Monoclonal antibodies currently in Phase II and III trials for multiple myeloma

Bibliography

• Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975-2007 [Internet] Bethesda (MD): National Cancer Institute. 2010. Available from: http://seer.cancer.gov/csr/1975_2007/index.html [Cited 26 November 2012]
   Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364(11):1046-60
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
   PubMed Web of Science ®Google Scholar
• Bladè J, Rosiñol L, Cibeira MT, et al. Hematopoietic stem cell transplatation for multiple myeloma beyond 2010. Blood 2010;115:3655-63
   PubMed Web of Science ®Google Scholar
• Facon T, Meletios A, Dispenzieri A, et al. Initial phase 3 results of the First (frontline investigation of lenalidomide + dexamethasone versus standard thalidomide) trial (MM-020/IFM 0701) in newly diagnosed multiple myeloma (NDMM) patients (pts) ineligible for stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2013;122:2
   Google Scholar
• Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011;118:1239-47
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple-myeloma. N Engl J Med 2005;352:2487-98
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42
   PubMed Web of Science ®Google Scholar
• Jagannath S, Kyle RA, Palumbo A, et al. The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma Leuk 2010;10:28-43
   PubMed Web of Science ®Google Scholar
• Kastritis E, Charidimou A, Varkaris A, et al. Targeted therapies in multiple myeloma. Br J Haematol 2009;141:135-48
   Google Scholar
• Di Bernardo A, Macor P, Guarnotta C, et al. Humoral immunotherapy of multiple myeloma; perspectives and perplexities. Expert Opin Biol Ther 2010;10:863-73
   PubMed Web of Science ®Google Scholar
• Campoli M, Ferris R, Ferrone S, Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 2010;16:11-20
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 2012;26:199-213
   PubMed Web of Science ®Google Scholar
• Weiner LM, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317-27
   PubMed Web of Science ®Google Scholar
• Beers SA, Chan CH, French RR, et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010;47:107-14
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. Immunophenotype and DNA cell content in multiple myeloma. Baillieres Clin Haemat 1995;8:735-59
   PubMed Web of Science ®Google Scholar
• Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t(4;14) in mulriple myeloma. Blood 2003;102:1070-1
   PubMed Web of Science ®Google Scholar
• Bergsagel P, Smith A, Szczepek A, et al. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995;85:436-47
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68
   PubMed Web of Science ®Google Scholar
• Hsu JW, Dang NH. The role of monoclonal antibodies in the treatment of lymphomas. Expert Opin Biol Ther 2013;13:227-39
   PubMed Web of Science ®Google Scholar
• Moreau P, Voillat L, Benboukher L, et al. Rituximab in CD20 positive multiple myeloma. Leukemia 2007;21:835-6
   PubMed Web of Science ®Google Scholar
• Zojer N, Kirchbacher K, Vesely M, et al. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma 2006;47:1103-9
   PubMed Web of Science ®Google Scholar
• Baz R, Fanning S, Kunkel L, et al. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leuk Lymphoma 2007;48(12):2338-44
   PubMed Web of Science ®Google Scholar
• Musto P, Carella AM Jr, Greco MM, et al. Short progression-free survivalin myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. Br J Haematol 2003;123:746-7
   PubMed Web of Science ®Google Scholar
• Lebovic D, Kaminski MS, Anderson TB, et al. A phase II study of consolidation treatment with iodione-131 tositumomab (Bexxar™) in multiple myeloma (MM). Blood (ASH Annual Abstract Meeting) 2012;120:abstract1854
   Google Scholar
• Tai YT, Dillon M, Song W, et al. CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytoxicity in the bone marrow milieu. Blood 2008;112:1329-37
   PubMed Web of Science ®Google Scholar
• Tai YT, Tonon G, Leiba M, et al. Cs1, a new surface target on multiple myeloma (MM) cells, protects myeloma cells from apoptosis via regulation of ERK 1/2, AKT and STAT3 signaling cascades. Blood (ASH Annual Meeting Abstracts) 2007;110:40
   Google Scholar
• Tassi I, Colonna M. The cytoxicity receptor CRACC(CS1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells. J Immunol 2005;175:7996-8002
   PubMed Web of Science ®Google Scholar
• Mentlik James A, Cohen AD, Campbell KS. Combination immunetherapies to enhance anti-tumor responses by Nkcells. Front Immunol 2013;4:481
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 2009;8:2616-24
   PubMed Web of Science ®Google Scholar
• Bensinger W, Zonder J, Singhal S, et al. Phase I trial of HuLuc63 in multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2007;110:358
   Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012;120:552-9
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012;30:1960-5
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012;30:1953-9
   PubMed Web of Science ®Google Scholar
• Facon T, Richardson PG, Jagannath S, et al. Phase (ph) I/II study of elotuzumab plus lenalidomide/dexamethasone (len/dex) in relapsed/refractory multiple myeloma (rr mm): updated ph II results and ph I/II long term safety. Abs Haematologica 2013;P764
   Google Scholar
• Richardson PG, Jagannath S, Moreau P, et al. Phase 2 study of elotuzumab plus lenalidomide/dexamethasone (len/dex) in relapsed/refractory multiple myeloma (rr mm) [abstract P214]. IMW Abstracts 2013;13(Suppl 1):s145
   Google Scholar
• Deaglio S, Metha K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001;25:1-12
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840-8
   PubMed Web of Science ®Google Scholar
• Tai YT, de Weers M, van der Veer MS, et al. Daratumumab, a novel potent human anti-CD38 monoclonal antibody, induces significant killing of human multiple myeloma cells: therapeutic cells : therapeutic implication. ASH Annual Meeting Abstracts 2009;114:608
   Google Scholar
• Van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011;96:284-90
   PubMed Web of Science ®Google Scholar
• van der Veer MS, de Weers M, van Kessel B, et al. Improved myeloma targeting by combination of the human anti-CD38 antibody daratumumab with lenalidomide and bortezomib. Blood (ASH Annual Meeting Abstracts) 2010;116:3030
   Google Scholar
• Kong SY, Li XF, Nahar S, et al. Daratumumab directly induces human multiple myeloma cell death and acts sinergistically with conventional and novel-antimyeloma drugs. Blood (ASH Annual Meeting Abstracts) 2010;116:3013
   PubMedGoogle Scholar
• Plesner T, Lokhorst H, et al. Daratumumab, a CD38 monoclonal antibody in PTS with multiple myeloma (MM)- Data from a dose-escalation PH I/II study [abstract P130]. IMW Abstracts 2013;13(Suppl 1):s105
   Google Scholar
• Lokhorst H, Plesner T, Gimsing P, et al. A CD38 monoclonal antibody study in advanced multiple myeloma - an open label, dose-escalation followed by open-label extension in a single arm phase I/II study [abstract S576]. EHA Abstract 2013;98(Suppl 1):241
   Google Scholar
• Plesner T, Arkenau T, Lokhorst H, et al. Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2013;122(21):1986
   Google Scholar
• Wijdenes J, Vooijs WC, Clément C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan 1. Br J Haematol 1996;94:318-23
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Abe E, Theus A, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, bone cell differentation. Blood 1998;91:2679-88
   PubMed Web of Science ®Google Scholar
• Ikeda H, Hideshima T, Fulciniti M, et al. The monoclonal antibody Nbt062 conjugated to cytotoxic mayntasinoids has selective cytoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009;15:4028-37
   PubMed Web of Science ®Google Scholar
• Zuber C, Daelken B, Aigner S, et al. A CD138 specific immunoconjugate, demonstrates superior in vivo anti-myeloma efficacy in combination with lenalidomide or bortezomib. ASH Annual Meeting Abstracts 2010;116:3008
   Google Scholar
• Jagannath S, Chanan-Khan A, Heffner LT, et al. BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed of relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstract) 2011;118:Abstract 305
   Web of Science ®Google Scholar
• Heffner LT, Jagannath S, Zimmerman TM, et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity. Blood (ASH Annual Meeting Abstract) 2012;120:Abstract 4042
   Google Scholar
• Kelly K, Chanan-Khan A, Somlo G, et al. Indatuximab ravtasine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in len/dex-refractory patients. ASH Annual Meeting Abstracts 2013;122(21):758
   Google Scholar
• Martinelli E, De Palma R, Orditura M, et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009;158:1-9
   PubMed Web of Science ®Google Scholar
• Mendelson J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;333:69-85
   Google Scholar
• Markman B, Capdevila J, Elez E, Tabernero J. New trends in epidermal growth factor receptor-directed monoclonal antibodies. Immunotherapy 2009;1:965-82
   PubMed Web of Science ®Google Scholar
• Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc) 2005;41:107-27
   PubMed Web of Science ®Google Scholar
• Mathouk K, Hose D, Rème T, et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 2005;24:3512-24
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Boell B, Eichenauer D, et al. Anti-epidermal growth factor receptor antibody cetuximab in relapsed or refractory multiple myeloma: a phase II prospective clinical trial. Leuk Lymphoma 2014;55(3):695-7
   PubMed Web of Science ®Google Scholar
• Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrin regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-26
   PubMed Web of Science ®Google Scholar
• Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Chen Q, Kuhn DJ, et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007;13:6469-78
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99:14374-9
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes preclinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009;145:481-90
   PubMed Web of Science ®Google Scholar
• Hunsucker SA, Magarotto V, Kuhn DJ, et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011;152:579-92
   PubMed Web of Science ®Google Scholar
• Van Zaanen HC, Lokhorst HM, Aarden LA, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-ecalating study. Br J Haematol 1998;102:783-90
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Fayad L, Voorhees PM, et al. A phase I study of CNTO 328, an anti-interleukin-6 monoclonal antibody in patients with B-cell non-Hodgkin's lymphoma, multiple myeloma or Castleman's disease. ASH Annual Meeting Abstracts 2008;112:1009
   Google Scholar
• Voorhees PM, Manges RF, Sonneveld P, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;161:357-66
   PubMed Web of Science ®Google Scholar
• San Miguel J, Bladé J, Samoilova OS, et al. Randomized, open label, phase 2 study of siltuximab (an anti-il6 mab) and bortezomib-melphalan-prednisone versus bortezomib-melphalan-prednisone in patients with previously untreated mutliple myeloma. EHA Abstracts 2013;98(s1):97 abstract P225
   Google Scholar
• Medinger M, Mross K. Clinical trials with anti-angiogenic agents in hematological malignancies. J Angiogenes Res 2010;2:10
   PubMedGoogle Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-73
   PubMed Web of Science ®Google Scholar
• Koldehoff M, Beelen DW, Elmaagacli AH. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma. J Leukoc Biol 2008;84:561-76
   PubMed Web of Science ®Google Scholar
• Ria R, Vacca A, Russo F, et al. A VEGF dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 2004;92:1438-45
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24(1):22-32
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2006;355:2542-342
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 2007;370:2103-11
   PubMed Web of Science ®Google Scholar
• Somlo G, Lashkari A, Bellamy W, et al. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a californinan cancer consortium trial. Br J Haematol 2011;154(4):533-5
   PubMed Web of Science ®Google Scholar
• White D, Kassim A, Bhaskar B, et al. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer 2013;119:339-47
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-95
   PubMed Web of Science ®Google Scholar
• Callander NS, Markovina S, et al. The addition of bevacizumab (B) to lenalidomide (L) and low dose dexamethasone does not significantly increase response in relapsed or refractory multiple myeloma [abstract 3885]. Blood (ASH Annual Meeting Abstracts) 2009;114:1495
   Web of Science ®Google Scholar
• Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmalastic signature. Blood 2005;106:1021-30
   PubMed Web of Science ®Google Scholar
• Neri P, Kumar S, Fulciniti MT, et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007;13:5903-9
   PubMed Web of Science ®Google Scholar
• Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004;103:3148-57
   PubMed Web of Science ®Google Scholar
• Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006;66:6675-82
   PubMed Web of Science ®Google Scholar
• Li LS, Shen JK, Zhang GS. [Effect of BAFF/APRIL mRNA expression induced by glucocorticoid and bortezomib in multiple myeloma cells in vitro]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011;19(6):1419-23
   PubMedGoogle Scholar
• Raje N, Faber E, Richardson P, et al. A phase 1 study of tabalumab and bortezomib (BTZ) in patients (pts) with previously treated multiple myeloma (MM) [abstract p155]. IMW Abstracts 2013;13(Suppl 1):s118
   Google Scholar
• Burkiewicz JS, Scarpace SL, Bruce SP. Denosumab in osteoporosis and oncology. Ann Pharmacother 2009;43:1445-55
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment; myeloma-osteoclast interactions as a model. Cancer Res 2004;64:2016-23
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2022;116:278-90
   Web of Science ®Google Scholar
• Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8
   PubMed Web of Science ®Google Scholar
• Vij R, Horvath N, Spencer A, et al. An open-label, phase 2 trial of denosumab in the tratment of relapsed or plateau-phase multiple myeloma. Am J Haematol 2009;84:650-6
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, von Moos R, Fallowfield LJ, et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 2012;23:3045-51
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94
   PubMed Web of Science ®Google Scholar
• Pinzone JJ, Hall BM, Thudi NK, et al. The role of Dickkopf-1 in bone development, homeostasis and disease. Blood 2009;113:517-25
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114:371-9
   PubMed Web of Science ®Google Scholar
• Padmanabhan S, Beck J, Kelly KR, et al. A phase I/II sttudy of BHQ880, a novel osteoblast activating, anti-DKK1 human monoclonal antibody, in relapsed and refractory multiple myeloma (MM) patients treated with zoledronic acid (Zol) and anti-myeloma therapy (MM Tx). Blood (ASH Annual Meeting Abstracts) 2009;114:Abstract 750
   Google Scholar
• Munshi NC, Abonour R, Beck JT, et al. Early evidence of anabolic bone activity of BHQ880, a fully human anti-DKK1 neutralizing antibody: results of a phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression. Blood (ASH Annual Meeting Abstracts) 2012;120:Abstract 331
   Google Scholar